Cytokinetics, Incorporated (CYTK)

NMS – Цена в реальном времени. Валюта: USD

74.81

+0.25 (0.34%)

При закрытии: May 12, 2026, 4:00 PM EDT

74.79

-0.02 (-0.03%)

После закрытия: May 12, 2026, 7:52 PM EDT

08.05.2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 1,478,873 additional shares, at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, were approximately $805 million. All of the shares of common stock in the offering were sold by Cytokinetics.

07.05.2026

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $700 million. The offering is expected to close on May 8, 2026, subject to customary closing conditions. Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional 1,478,873 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering will be sold by Cytokinetics.

06.05.2026

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.

06.05.2026

Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript

05.05.2026

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Cytokinetics (CYTK) came out with a quarterly loss of $1.67 per share in line with the Zacks Consensus Estimate. This compares to a loss of $1.36 per share a year ago.

05.05.2026

Cytokinetics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $650 million of shares of its common stock in an underwritten public offering.

05.05.2026

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

U.S. Launch of MYQORZO ® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance; Full Results to be Presented at Upcoming Medical Congress MYQORZO Approved by the European Commission for Adults with Symptomatic Obstructive HCM;Supplemental NDA for MAPLE-HCM Accepted for Filing by FDA with PDUFA Date of November 14, 2026 Net Product Revenues for MYQORZO of $4.8 Million for Initial Partial Quarter; ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the first quarter of 2026.

Видео

28.10.2025

Positive

Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
CYTK	Raymond James	Market Perform	undefined >> undefined	July 30th 2025

Пресс-релизы

08.05.2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

07.05.2026

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

05.05.2026

Cytokinetics Announces Proposed Public Offering of Common Stock

05.05.2026

Cytokinetics, Incorporated (CYTK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Cytokinetics, Incorporated (CYTK)

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Cytokinetics Announces Proposed Public Offering of Common Stock

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

Видео

Повышения / Понижения рейтинга

Пресс-релизы

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

Cytokinetics Announces Proposed Public Offering of Common Stock

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Cytokinetics Announces Proposed Public Offering of Common Stock

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

Видео

Повышения / Понижения рейтинга

Пресс-релизы

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

Cytokinetics Announces Proposed Public Offering of Common Stock

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

Search stocks

Cytokinetics, Incorporated (CYTK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Cytokinetics, Incorporated (CYTK)

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Cytokinetics Announces Proposed Public Offering of Common Stock

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

Видео

Повышения / Понижения рейтинга

Пресс-релизы

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

Cytokinetics Announces Proposed Public Offering of Common Stock

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Cytokinetics Announces Proposed Public Offering of Common Stock

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

Видео

Повышения / Понижения рейтинга

Пресс-релизы

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

Cytokinetics Announces Proposed Public Offering of Common Stock

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update